Erlotinib belongs to the first generation of targeted drugs

Erlotinib is a first-generation targeted drug. Targeted drugs are usually divided into three generations based on their development time and characteristics. Each generation of targeted drugs is different in terms of mechanism of action, efficacy and side effects. The first generation of targeted drugs mainly targets specific molecular targets and achieves therapeutic purposes by inhibiting the growth and spread of tumor cells.

Erlotinib, an oral small molecule tyrosine kinase inhibitor (TKI), is one of the representatives of the first generation of targeted drugs. It mainly targets cancer patients with EGFR (epidermal growth factor receptor) mutations, preventing the growth and spread of cancer cells by inhibiting the activity of the EGFR signaling pathway.

The first generation of targeted drugs usually target specific molecular targets, such as EGFR, ALK, etc. This specificity allows the drug to act on tumor cells more accurately and reduce damage to normal cells.

For patients with tumors carrying specific genetic mutations, first-generation targeted drugs can often achieve significant results, extending the patient's survival and improving their quality of life.

Although the first generation of targeted drugs are excellent in efficacy, they may also cause specific side effects, such as rash, diarrhea, liver damage, etc. In addition, with the prolongation of treatment time, some patients may develop drug resistance.

Erlotinib is mainly used clinically to treat tumor diseases such as non-small cell lung cancer (NSCLC) and pancreatic cancer. For patients with NSCLC mutations in the EGFR gene, erlotinib can significantly extend the progression-free survival and overall survival of the patients. However, it should be noted that erlotinib is not suitable for all NSCLC patients, and its efficacy and safety vary depending on individual patients.